COST EFFECTIVENESS ANALYSIS OF PEGYLATED LIPOSOMAL AND NONLIPOSOMAL DOXORUBICIN FORMULATIONS FOR THE FIRST LINE TREATMENT OF METASTATIC BREAST CANCER FROM PATIENT PERSPECTIVE IN EGYPT

Author(s)

Assal RA1, Hamdy El-sisi G2
1German University in Cairo, Cairo, Egypt, 2Heliopolis University, Cairo, Egypt

OBJECTIVES:

Breast cancer (BC) is the most frequent cancer among women worldwide according to WHO. Its poor prognosis, high metastatic potential and high mortality rate highlights the compelling need for superior, less toxic, and more cost-effective anticancer formulations in comparison to conventional formulations.

National comprehensive cancer network (NCCN) guidelines for 2018 recommend the use of the highly potent Doxorubicin, the anthracycline antineoplastic antibiotic, as first line in women with metastatic/late-stage breast cancer at diagnosis as initial monotherapy. Doxorubicin comes in different formulations; pegylated liposomal doxorubicin (PLD) and nonliposomal doxorubicin conventional formulation.

To date, cost-effectiveness of PLD is still not well defined. PPLD and doxorubicin had comparable efficacies with respect to OS and PFS. However, overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16).

This study aimed at performing cost effectiveness analysis for PLD and nonliposomal doxorobucin as a 5-year initial therapy for first line management of metastatic BC from patient’s perspective in Egypt.

METHODS:

Direct medical costs were reported in Egyptian pounds (EGP) of the financial year 2018 (1 USD=17.88 EGP). Doses of PLD and nonliposomal doxorubicin IV are 50 mg/m (every 4 weeks) and 60 mg/m (every 3 weeks), respectively. Discounting (6%) and one-way sensitivity analysis (+/- 25%) were conducted. National threshold in Egypt = 70,000 EGP.

RESULTS:

Five-year direct medical costs for PLD and nonliposomal doxorubicin were EGP 285,730 and EGP 6,570 respectively. ICER for PLD compared to nonliposomal doxorubicin is 88,342 EGP/extra avoided case of cardiotoxicity. Since ICER exceeds the national threshold then PLD is not cost effective. Results were insensitive to change.

CONCLUSIONS:

In conclusion, PLD is not the more preferred option compared to nonliposomal doxorobucin formulation as a 5-year initial monotherapy for the first line management of metastatic BC from patient’s perspective in Egypt as it is not cost effective (ICER exceeds national threshold).

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PCN160

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×